Oramed Pharmaceuticals (ORMP) Q4 2024 earnings summary

Executive summary

• Focused on oral delivery of therapeutic proteins, with a primary asset in oral insulin for diabetes treatment. Clinical setbacks in 2023 led to a strategic review and pipeline evaluation, including a new Phase 3 trial protocol submitted to the FDA in September 2024, targeting responsive subpopulations. Strategic partnerships and investments, including a joint venture (OraTech) with HTIT and significant financial transactions with Scilex, have diversified operations and capital allocation.

• Entered into a joint venture with HTIT to develop and commercialize oral insulin, with a planned spin-off of OraTech and significant capital commitments from both parties. Additional investments include real estate and equity stakes in BioXcel and Scilex.

Financial highlights

• Reported a net loss of $19.1 million for 2024, compared to net income of $5.1 million in 2023, primarily due to the absence of revenue and lower financial income.

• No revenue recognized in 2024 (vs. $1.3 million in 2023) due to the completion of revenue recognition from the HTIT license agreement.

• Research and development expenses decreased 30% year-over-year to $6.3 million, reflecting reduced clinical activity after trial terminations.

• General and administrative expenses decreased 23% to $6.5 million, mainly due to executive departures.

• Cash and cash equivalents increased to $54.4 million as of December 31, 2024, with total current assets of $143.2 million and working capital surplus of $137.5 million.

• Investments at fair value (mainly Scilex-related notes and warrants) totaled $34.8 million at year-end.

Outlook and guidance

• Plans to initiate a revised Phase 3 oral insulin trial in 2025, focusing on patient subpopulations with higher efficacy potential.

• Ongoing evaluation of strategic alternatives, including potential business combinations, acquisitions, or capital raises.

• Research and development expenses expected to increase with the new clinical trial, though costs may be borne by OraTech.

• Real estate investments and other non-core activities are intended to enhance financial flexibility and shareholder value.